Sugi Predict

Sugi Predict / Compounds / SCHEMBL3409732

SCHEMBL3409732

SCHEMBL3409732

Nc1ccc(-c2nc(-c3ccccc3)c(-c3ccccc3)[nH]2)cc1

nearest known ligand 0.79

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 13/20 0.71
▸ MAPK13 O15264 12/20 0.71
▸ MAPK12 P53778 12/20 0.71
▸ MAPK11 Q15759 12/20 0.71
▸ GCGR P47871 7/20 0.71
▸ RAF1 P04049 4/20 0.69
▸ MAPK9 P45984 1/20 0.68
▸ NOX1 Q9Y5S8 1/20 0.65
▸ ALOX5 P09917 2/20 0.64
▸ TP53 P04637 1/20 0.61
▸ MAPT P10636 1/20 0.61
▸ BRAF P15056 1/20 0.61
▸ KDM4E B2RXH2 1/20 0.60
▸ ALDH1A1 P00352 1/20 0.60
▸ GLA P06280 1/20 0.60
▸ GAA P10253 1/20 0.60
▸ HPGD P15428 1/20 0.60
▸ KMT2A Q03164 1/20 0.60
▸ PTPN1 P18031 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16497639 0.92 MAPK14 (0.83) MAPK14MAPK13MAPK12MAPK11GCGR
Hydrochloric Acid SCHEMBL29622996 0.91 MAPK14 (0.69) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL5074753 0.91 MAPK13 (0.83) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL16667652 0.89 MAPK13 (0.83) MAPK14MAPK13MAPK12MAPK11GCGR
Benzene SCHEMBL28852698 0.89 MAPK13 (0.82) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL104130 0.89 MAPK13 (0.82) MAPK14MAPK13MAPK12MAPK11GCGR
Methane SCHEMBL3278320 0.87 MAPK13 (0.79) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL27850480 0.87 MAPK13 (0.79) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL3456136 0.83 MAPK13 (0.74) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL28819760 0.83 PTPN1 (0.64) MAPK14MAPK13MAPK12MAPK11GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111403758-B Nitrogen-doped carbon catalyst and preparation method and application thereof 湘潭大学 2021-04-30 — — CN claimed
CN-111403758-A Nitrogen-doped carbon catalyst and preparation method and application thereof 湘潭大学 2020-07-10 — — CN claimed
US-20070259875-A1 Triaryl substituted imidazole derivatives and taste-inhibiting uses thereof REDPOINT BIO CORPORATION 2007-11-08 — — US claimed
CN-111403758-B Nitrogen-doped carbon catalyst and preparation method and application thereof 湘潭大学 2021-04-30 — — CN disclosed
CN-111403758-A Nitrogen-doped carbon catalyst and preparation method and application thereof 湘潭大学 2020-07-10 — — CN disclosed
CN-104151307-A Schiff base compound containing benzooxazole ring and iminazole ring and preparation method thereof SHANGRAO NORMAL UNIVERSITY 2014-11-19 — — CN disclosed
CN-103664931-A Schiff base compound containing benzothiazole ring and imidazole ring, and preparation method thereof SHANGRAO NORMAL UNIVERSITY 2014-03-26 — — CN disclosed
US-8669033-B2 Electrophotographic toner and production method of the same KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) 2014-03-11 — — US disclosed
US-8669033-B2 Electrophotographic toner and production method of the same KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) 2014-03-11 — — US disclosed
EP-2264542-B1 Toner and manufacturing method thereof KONICA MINOLTA BUSINESS TECH (JP) 2013-01-09 — — EP disclosed
US-8304157-B2 Toner and manufacturing method thereof KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) 2012-11-06 — — US disclosed
CN-101930188-A Toner and manufacture method thereof KONICA MINOLTA BUSINESS TECH 2010-12-29 — — CN disclosed
US-20100323290-A1 TONER AND MANUFACTURING METHOD THEREOF KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) 2010-12-23 — — US disclosed
EP-2264542-A1 Toner and manufacturing method thereof Konica Minolta Business Technologies, Inc. (JP) 2010-12-22 — — EP disclosed
EP-2015638-A2 TRIARYL SUBSTITUTED IMIDAZOLE DERIVATIVES AND TASTE-INHIBITING USES THEREOF Redpoint Bio Corporation (US) 2009-01-21 — — EP disclosed
US-20070259875-A1 Triaryl substituted imidazole derivatives and taste-inhibiting uses thereof REDPOINT BIO CORPORATION 2007-11-08 — — US disclosed
US-20070259875-A1 Triaryl substituted imidazole derivatives and taste-inhibiting uses thereof REDPOINT BIO CORPORATION 2007-11-08 — — US disclosed
US-20070259875-A1 Triaryl substituted imidazole derivatives and taste-inhibiting uses thereof REDPOINT BIO CORPORATION 2007-11-08 — — US disclosed
WO-2007127479-A2 TRIARYL SUBSTITUTED IMIDAZOLE DERIVATIVES AND TASTE-INHIBITING USES THEREOF REDPOINT BIO CORPORATION (US) 2007-11-08 — — WO disclosed
WO-2007127479-A2 TRIARYL SUBSTITUTED IMIDAZOLE DERIVATIVES AND TASTE-INHIBITING USES THEREOF REDPOINT BIO CORPORATION (US) 2007-11-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259875-A1 Triaryl substituted imidazole derivatives and taste-inhibiting uses thereof TAS1R3, TAS2R1, TAS1R1 MAPK14 4278/4885MAPK13 3416/4885MAPK12 4112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.